From 1986 to 1993, Mr Mundasad worked at the Princess of Wales Hospital and Eye Treatment Centre, Bridgend. Since then he has worked as a Clinical Fellow and Hon. Research Fellow at the department of Ophthalmology, University of Bristol. From 1996 he has been working as an Associate Specialist at Bristol Eye Hospital.

In 1998 he was one of the very few who successfully completed the refractive surgery course and examination held by the European Society of Cataract and Refractive Surgeons in Nice.

He has successfully performed over 2000 laser treatments at Optimax and to date has completed over two thousand laser treatments in the NHS for various eye conditions.

During 1986, he was the first eye specialist in Wales to use Botulinum Toxin as a research drug to treat patients with Facial Dystonia, which has now become an accepted way of treating various forms of Dystonia. He continues to be actively involved in Clinical Research and has recently completed a clinical trial for a new drug for dry eyes in collaboration with a pharmaceutical Research Company in North Carolina. He presented research findings at the ARVO Florida, on the new formulation to treat dry eyes during 2000-2001 and a novel method of non invasive delivery of drugs to the laser vision correction specialists during May 2002.

Mr Mundasad joined Optimax in 1996. He has successfully performed over 1800 laser treatments at Optimax and to date has completed over two thousand laser treatments in the NHS for various eye conditions.

Mr Mundasad is a member of British Society for Refractive Surgery, The European Sociey of Cataract and Refractive Surgery, British Medical Association, ARVO(Association for Research in Vision and Ophthalmology) and South West Ophthalmic Society, Oxford Ophthalmological Congress.

Audits Done between 2003 and 2004:

1. Clinical Outcomes of Laser Treatment for Diabetic Maculopathy
2. Clinical Outcomes of Phototherapeutic Keratectomy (is selected for regional audit presentation at the Royal College of Ophthalmology conference 2005 and won the first prize for best presentation at SWOS meeting at Bristol)
3. One stop service lid surgery outcomes

Publications:

1. Journal of Ocular Pharmacology and Therapeutics Number 2, 2003:
   Tolerance of Ocular Iontophoresis in Healthy Volunteers
2. Journal of Ocular Pharmacology and Therapeutics Number 2, 2001:
   Ocular Safety of INS365 Ophthalmic Solution: A P2Y2 Agonist In Healthy Subject
3. Lacrimal Gland , Tear film and Dry Eye Syndromes : Ocular Safety of INS365 Ophthalmic Solution in patients with mild to moderate dry eye disease

RESEARCH WORK:

1. Study of Pemirolast-K topical ophthalmic preparation. Safety and Tolerance in healthy volunteers. 1993
2. Study of Tolerance and Comfort comparison TBX, DSCG, Normal Saline and TBX Vehicle Double blind phase I. 1994
3. Tolerance/Comfort comparison of TBX 0.01%, 0.1%, 0.25%, and TBX Vehicle. 1994
4. Tolerance/Comfort Comparison of 0.1 & TBX, 2%Nedocromil, 0.1 % Lodoxamide, 4%DSCG and 0.9% Sodium Chloride. 1995
5. Parallel, Double-masked, Placebo-controlled Study of the effectiveness and safety of Alpha-Blocker eye drops in treatment of Ocular hypertensive subjects. 1997-98
6. A Single exposure, Ascending dose, Randomised, Placebo-controlled, Double Blind Study of a new Topical Ophthalmic Antithepetic preparation. 1999
7. A Double-masked, Randomised, Paired Comparison, Dose-Escalation study of the Ocular Safety and Efficacy of INS 365 Ophthalmic Solution in Normal Subjects. 1999
8. A Study to Evaluate the Antibiotic in Tear Fluid after Instillation of a Gel Eye Drops Formulation. 1999
9. A Double-masked, Randomised, Placebo-controlled, rising dose study of multiple ocular Instillations of INS 365 Ophthalmic Solution in patients with mild to moderate dry eye disease. May 2000
10. Study to determine Plasma levels of Tobramycin and Dexametasone following topical dosing Tobradex eye drops in volunteers. 2000
11. Phase I Double Blind, Placebo-controlled, Ascending multiple oral dose safety, Tolerability and Pharmacokinetics and preliminary pharmacodynamic study of TAK-427 in healthy volunteers
12. Ocular iontophoresis - phase I trial
13. Ocular safety of INS 365 ophthalmic solution P2Y2 agonist in healthy subjects
14. INS 365 in patients with mild to moderate dry eye disease
15. Ecabet-Na in patients with mild to moderate dry eye disease